Application of CRISPR/Cas9 Technology to HBV
AbstractMore than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (cccDNA), which acts as a transcription template for viral mRNA and pre-genomic RNA synthesis and secures virus persistence. Thus, the fact that only a small number of patients treated achieve sustained viral response (SVR) or cure, highlights the need for new therapies against HBV. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system can specifically target the conserved regions of the HBV genome. This results in robust viral suppression and provides a promising tool for eradicating the virus. In this review, we discuss the function and application of the CRISPR/Cas9 system as a novel therapy for HBV. View Full-Text
Share & Cite This Article
Lin, G.; Zhang, K.; Li, J. Application of CRISPR/Cas9 Technology to HBV. Int. J. Mol. Sci. 2015, 16, 26077-26086.
Lin G, Zhang K, Li J. Application of CRISPR/Cas9 Technology to HBV. International Journal of Molecular Sciences. 2015; 16(11):26077-26086.Chicago/Turabian Style
Lin, Guigao; Zhang, Kuo; Li, Jinming. 2015. "Application of CRISPR/Cas9 Technology to HBV." Int. J. Mol. Sci. 16, no. 11: 26077-26086.